Fred Aslan is Chief Executive Officer of Artiva Biotherapeutics, Inc. (ARTV). The company reported total compensation of $6,671,215 for fiscal year 2025.
| Salary | $665,000 |
|---|---|
| Bonus | $0 |
| Stock awards | $5,455,700 |
| Option awards | $0 |
| Non-equity incentive plan | $536,281 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $14,234 |
| Total | $6,671,215 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Artiva Biotherapeutics, Inc. filed August 3, 2026, accession 0001193125-26-330563.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Fred Aslan this page | Chief Executive Officer | $6,671,215 |
| Jennifer Bush | Chief Operating Officer, Chief Legal Officer and Compliance Officer | $1,536,715 |
| Christopher Horan | Chief Technical Operations Officer | $1,415,855 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Artiva Biotherapeutics, Inc. compensation brief.
Fred Aslan's compensation sits inside Artiva Biotherapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.